Education
About Us
Working with TipRanks
Follow Us
Sinopharm Group Co Class H (HK:1099)
:1099
Total Valuation
Sinopharm Group Co has a market cap or net worth of HK$57.82B. The enterprise value is ―.
Market CapHK$57.82B
Enterprise Value―
Share Statistics
Sinopharm Group Co has 1,341,810,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,341,810,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sinopharm Group Co’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 5.82%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)5.82%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee5.40M
Profits Per Employee129.38K
Employee Count108,217
Asset Turnover1.49
Inventory Turnover8.66
Valuation Ratios
The current PE Ratio of Sinopharm Group Co is 8.86. Sinopharm Group Co’s PEG ratio is -0.40.
PE Ratio8.86
PS Ratio0.00
PB Ratio0.68
Price to Fair Value0.79
Price to FCF5.87
Price to Operating Cash Flow4.61
PEG Ratio-0.40
Income Statement
In the last 12 months, Sinopharm Group Co had revenue of 584.51B and earned 7.05B in profits. Earnings per share was 2.26.
Revenue584.51B
Gross Profit44.26B
Operating Income16.19B
Pretax Income14.00B
Net Income7.05B
EBITDA20.17B
Earnings Per Share (EPS)2.26
Cash Flow
In the last 12 months, operating cash flow was 11.55B and capital expenditures -2.46B, giving a free cash flow of 9.09B billion.
Operating Cash Flow11.55B
Free Cash Flow9.09B
Free Cash Flow per Share6.77
Dividends & Yields
Sinopharm Group Co pays an annual dividend of HK$0.729, resulting in a dividend yield of 5.2%
Dividend Per ShareHK$0.729
Dividend Yield5.2%
Payout Ratio37.55%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.74
52-Week Price Change-7.71%
50-Day Moving Average18.41
200-Day Moving Average19.49
Relative Strength Index (RSI)53.67
Average Volume (3m)6.04M
Important Dates
Sinopharm Group Co upcoming earnings date is Sep 1, 2025, TBA Not Confirmed.
Last Earnings DateApr 25, 2025
Next Earnings DateSep 1, 2025
Ex-Dividend DateJun 16, 2025
Financial Position
Sinopharm Group Co as a current ratio of 1.39, with Debt / Equity ratio of 96.83%
Current Ratio1.39
Quick Ratio1.14
Debt to Market Cap1.14
Net Debt to EBITDA1.09
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Sinopharm Group Co has paid 3.58B in taxes.
Income Tax3.58B
Effective Tax Rate0.26
Enterprise Valuation
Sinopharm Group Co EV to EBITDA ratio is 4.19, with an EV/FCF ratio of 8.82.
EV to Sales0.14
EV to EBITDA4.19
EV to Free Cash Flow8.82
EV to Operating Cash Flow7.32
Balance Sheet
Sinopharm Group Co has HK$54.31B in cash and marketable securities with ¥76.39B in debt, giving a net cash position of HK$22.07B billion.
Cash & Marketable SecuritiesHK$54.31B
Total Debt¥76.39B
Net CashHK$22.07B
Net Cash Per ShareHK$16.45
Tangible Book Value Per ShareHK$37.73
Margins
Gross margin is 7.57%, with operating margin of 2.77%, and net profit margin of 1.21%.
Gross Margin7.57%
Operating Margin2.77%
Pretax Margin2.40%
Net Profit Margin1.21%
EBITDA Margin3.45%
EBIT Margin3.05%
Analyst Forecast
The average price target for Sinopharm Group Co is HK$23.35, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$23.35
Price Target Upside25.96% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-3.94%
EPS Growth Forecast-23.48%